| Rx0000072 |
Mayne Pharma Inc |
04/11/2025 |
51862076530 |
Rhofade 1 g/100 g cream 30 g tube |
02/01/2025 |
60.74 |
735.58 |
06/11/2035 |
Single Source Drug |
None |
None |
None |
1 |
Recent changes in market dynamics and heightened competition have led us to adapt our approach to ensure continued growth and success strategically. As the competitive landscape evolves, we have focused on enhancing our offerings, improving efficiency, and investing in innovation to better meet customer needs and expectations. These adjustments are essential for maintaining our position in the market and delivering exceptional value, ensuring that we remain well-positioned to thrive in an increasingly competitive environment. |
None |
No change or improvement. |
None |
09/04/2023 |
EPI Health LLC |
8000000 |
None |
None |
568.00 |
568.00 |
2024 |
674.84 |
None |
Mayne Pharma Commercial LLC (Mayne Pharma) previously notified CA of an NDC change for Rhofade (""the Product"") from 71403000330 to 51862076530. The qualifying WAC increase went into effect on the same day the new NDC (51862076530) went into effect. For clarity, no changes to the Product or Product formulation have occurred, and no changes are anticipated at this time. Accordingly, the initial decision by Mayne Pharma to increase the WAC for the Product was in no way based on, or related to, any change or improvement in the Product. Rather the decision to increase the WAC was based on other factors including, but not limited to, the value of the treatment and market dynamics related to the Product.
Please see the 5-year WAC increase history under the prior NDC (71403000330).
WAC Effective Date: 06/01/2024, WAC Increase Amount 55.72, WAC After Increase 674.84;
WAC Effective Date: 9/20/2023, WAC Increase Amount 51.12, WAC After Increase 619.12;
WAC Effective Date: 04/01/2022, WAC Increase Amount 24.46, WAC After Increase 568.00;
WAC Effective Date: 1/19/2021, WAC of 543.54 |
| Rx0000138 |
Merck Sharp & Dohme LLC |
04/16/2025 |
00006542312 |
BRIDION 10 200 mg/2 mL VIAL (ML) |
01/06/2025 |
64.80 |
1361.40 |
07/27/2026 |
Single Source Drug |
None |
None |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments.
We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines. |
None |
There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. |
| Rx0000138 |
Merck Sharp & Dohme LLC |
04/16/2025 |
00006542515 |
BRIDION 10 500 mg/5 mL VIAL (ML) |
01/06/2025 |
118.50 |
2493.50 |
07/27/2026 |
Single Source Drug |
None |
None |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments.
We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines. |
None |
There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. |
| Rx0000138 |
Merck Sharp & Dohme LLC |
04/16/2025 |
52015008001 |
DIFICD 20 200 mg Tablets |
01/06/2025 |
224.20 |
5205.00 |
01/15/2024 |
Single Source Drug |
None |
None |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments.
We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines. |
None |
There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. |
| Rx0000138 |
Merck Sharp & Dohme LLC |
04/16/2025 |
52015070022 |
DIFICID 1 packet granules (40mg/mL final concentration) Suspension-Reconsitituted-Oral (EA) |
01/06/2025 |
224.20 |
5205.00 |
01/15/2024 |
Single Source Drug |
None |
None |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments.
We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines. |
None |
There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. |
| Rx0000138 |
Merck Sharp & Dohme LLC |
04/16/2025 |
67919003001 |
ZERBAXA 10 1.5 gram VIAL (EA) |
01/06/2025 |
157.10 |
1743.60 |
05/15/2028 |
Single Source Drug |
None |
None |
None |
1 |
Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments.
We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines. |
None |
There is no specific change or improvement to the listed product that would necessitate a change in the products Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the products active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a products patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product. |
| Rx0000603 |
Merz Pharmaceuticals, LLC |
04/21/2025 |
10144042760 |
Ampyra Oral Tablet Extended Release 12 Hour 10 MG Package Quantity 1 Bottle of 60 Tablets |
01/01/2025 |
212.85 |
4469.76 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
07/10/2024 |
Acorda Therapeutics |
None |
1 |
None |
4256.91 |
3869.92 |
2010 |
1056.16 |
None |
None |
| Rx0000603 |
Merz Pharmaceuticals, LLC |
04/21/2025 |
10144034260 |
Inbrija Inhalation Capsule 42 MG Package Quantity 1 Bottle of 60 Tablets |
01/01/2025 |
61.06 |
1282.30 |
11/16/2032 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
07/10/2024 |
Acorda Therapeutics |
None |
1 |
None |
1221.24 |
1152.12 |
2019 |
950.00 |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
04/28/2025 |
72495020105 |
Femring Vaginal Ring 1 pouch in 1 carton; 1 ring in 1 pouch (0.05 mg/day) |
01/09/2025 |
70.80 |
832.12 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
04/28/2025 |
72495020210 |
Femring Vaginal Ring 1 pouch in 1 carton; 1 ring in 1 pouch (0.1 mg/day) |
01/09/2025 |
75.45 |
886.73 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000051 |
MILLICENT U.S., INC. |
04/28/2025 |
72495040128 |
Intrarosa Vaginal Insert 28 blister pack in 1 box; 1 insert in 1 blister Pack (6.5 mg insert) |
01/09/2025 |
24.08 |
294.63 |
03/19/2031 |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
05/01/2020 |
AMAG |
125000000 |
None |
None |
212.30 |
202.00 |
2017 |
175.00 |
None |
None |
| Rx0000397 |
Mirum Pharmaceuticals |
04/30/2025 |
68974087640 |
CHENODAL TABLETS 1 PACK 100 TABS 250 MG |
01/01/2025 |
4783.14 |
57929.14 |
None |
Single Source Drug |
None |
None |
None |
1 |
Mirum's pricing strategy reflects a careful evaluation of multiple elements, such as competitive market conditions, increasing supply chain and operational costs, distribution and wholesaler fees, along with research and development expenditures. Small patient popuations reflect pricing of products. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |